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Background. Controversy exists regarding the possible as-
sociations between a single nucleotide polymorphism of the
transcobalamin II encoding gene (TCN2 776C>G) and plasma
levels of vitamin B12, folate, or total homocysteine.
Methods. In a cross-sectional study of 732 kidney allograft
recipients, patients were categorized by TCN2 776C>G geno-
type. In univariate and multivariate linear regression models
that allowed the outcome variables vitamin B12, folate, and total
homocysteine plasma levels to follow a gamma distribution, we
tested for possible associations of allelic variants of the TCN2
776C>G gene and these three dependent variables.
Results. The allele frequency for TCN2 776C>G was 0.46.
Heterozygosity or homozygosity for TCN2 776C>G was not
associated with plasma levels of vitamin B12 (776CG, P = 0.22;
776GG, P = 0.89), folate (776CG, P = 0.91; 776GG, P = 0.84),
or total homocysteine (776CG, P = 0.11; 776GG, P = 0.33) even
after adjustment for several possible confounders.
Conclusion. We conclude from this largest study on the sub-
ject thus far that there are no associations between allelic vari-
ants of TCN2 776C>G and plasma vitamin B12, folate, or total
homocysteine plasma levels in kidney transplant patients.
Elevated plasma total homocysteine is an established
risk factor for various cardiovascular outcomes as well
as for neural tube defects.[1, 2] The relevance of to-
tal homocysteine as a risk factor is even more pro-
nounced in patients with chronic kidney disease, or on
renal replacement therapy, due to an altered homocys-
teine metabolism in such patients.[3] A fast-growing area
of research has focused on the detection of mutations
in specific genes encoding enzymes that are involved in
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the homocysteine metabolism. It has been hypothesized
for several of these mutations to be related to increases
in total homocysteine plasma levels, either directly, or
via changes in other factors involved in the homocys-
teine metabolism, such as folic acid or vitamin B12. While
there is wide agreement that the mutation at nucleotide
position 677 in the 5,10-methylenetetrahydrofolate
reductase gene (MTHFR 677C>T) is related to hyper-
homocysteinemia [4], such effects could not be demon-
strated for other single nucleotide polymorphisms in the
MTHFR encoding gene (e.g., 1298A>C) or those encod-
ing other enzymes such as the reduced folate carrier 1
gene (RFC1 80G>A),[5, 6] the glutamate carboxypepti-
dase II gene (GCP2 1561C>T),[5, 6] and the methionine
synthase reductase gene (MTRR 66A>G) [7].
As summarized previously, three proteins are involved
in vitamin B12 transport in the human body [8]. In the
stomach, vitamin B12 binds to intrinsic factor that is es-
sential for the intestinal vitamin uptake. In the plasma,
20% to 30% of vitamin B12 is bound to transcobalamin
II (TC II). The complex of vitamin B12 bound to TC II is
termed holo-transcobalamin II (holo-TC II). The cellular
supply with vitamin B12 is therefore related to the con-
centration of holo-TC II in the circulation. Consequently,
low holo-TC II concentrations may be an early indicator
of vitamin B12 deficiency. The remaining 70% to 80% of
vitamin B12 are bound to haptocorrin, the role of which is
not completely understood, but that may act as a storage
protein.
A polymorphism (TCN2 776C>G; P259R) in the TC
II gene (TCN2) may have an effect on the concentra-
tion of blood TC II [9]. In healthy Caucasian individu-
als with the TCN2 CC genotype, TC II concentrations
were higher as compared to heterozygotes or individuals
homozygous for the G allele. Furthermore, heterozy-
gotes showed higher total homocysteine plasma concen-
trations as compared to both homozygous genotypes
suggesting that TCN2 776C>G interferes with vitamin
B12 cellular delivery and homocysteine metabolism [9].
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Table 1. Characteristics of 732 kidney graft recipients
Mean (±standard deviation),
Variable Median (25th/75th percentile)
Age years 51.8 (±13.5)
Female gender 39.9%
Body mass index kg/m2 25.3 (±4.3)
Estimated glomerular filtration 55.9 (±20.0)
rate mL/min
Years since transplantation 5.0 (±4.1)
Plasma vitamin B12 pmol/L 219 (169/308)
Plasma folate nmol/L 13.0 (10.0/16.9)
Plasma total homocysteine lmol/L 15.0 (11.9/19.8)
Likely underlying renal disease
Glomerulonephritis 34.0%
Polycystic kidney disease 13.6%
Interstitial nephritis 16.6%
Diabetic nephropathy 6.6%
Various other renal diseases 8.6%
Unknown renal disease 20.6%
By contrast, others observed no major effect of TCN2
776C>G on plasma total homocysteine and plasma vita-
min B12 concentration as well as a decrease of holo-TC
II concentrations, raising the question of the impact of
TCN2 776C>G on vitamin B12 cellular delivery and total
homocysteine concentrations [8, 10–12]. One study even
described lower total homocysteine concentrations in in-
dividuals in the upper quartile of vitamin B12 levels with
the TCN2 776GG genotype [13]. A detailed discussion
of the existing literature on the TCN2 776C>G polymor-
phism and total homocysteine levels has recently been
published [14].
In light of the rather conflicting evidence on the role of
the TCN2 776C>G mutation, we conducted the present
study. We specifically aimed to describe the respective fre-
quencies of the TCN2 776C>G allelic variants in a large
cohort of patients with a functioning kidney transplant,
and to test the hypothesis whether these genetic charac-
teristics were independently associated with vitamin B12,
folate, or total homocysteine plasma levels.
METHODS
Study population
To assess the associations between vitamin B12, folate,
and total homocysteine plasma levels, and TCN2 geno-
type status, we conducted a cross-sectional study of 733
kidney allograft recipients who received routine follow-
up at our institution. The detailed rules for study inclusion
have been published elsewhere [15]. Material for genetic
analysis was unavailable for one individual, which left a fi-
nal study population of 732 patients. None of the patients
received routine folic acid or vitamin B supplementation.
Important patient characteristics are shown in Table 1.
All patients provided written informed consent accord-
ing to the Declaration of Helsinki and the Austrian Law
on Gene Technology.
Biochemical methods
Fasting citrated blood was immediately placed on
ice, and centrifuged at 2000 × g at 4◦C (20 minutes)
within 60 minutes. Plasma aliquots and 500 lL of cit-
rated blood for isolation of DNA were snap-frozen and
stored at −70◦C. Plasma concentrations of total homocys-
teine (free plus protein-bound homocysteine)[16] were
determined by automated high-performance liquid chro-
matography (HPLC) with reversed-phase separation and
fluorescence detection using tri-n-butylphosphine as a re-
ducing agent. Hyperhomocysteinemia was defined as to-
tal homocysteine levels above 15 lmol/L [16]. Intra-assay
variability was between 1.4% and 1.7% and interassay
variability was between 1.5% and 1.9% for total ho-
mocysteine concentrations of 15.9 and 6.9 lmol/L, re-
spectively. Folate and vitamin B12 plasma levels were
measured with a radioassay (SimulTRAC-SNB, ICN
Pharmaceuticals Inc., Costa Mesa, CA, USA). Folate de-
ficiency was defined as a plasma concentration of less
than 3.4 nmol/L, and vitamin B12 deficiency was defined
as a plasma concentration of less than 118 pmol/L, re-
spectively. Interassay variability was 4% to 5% for folate
measurements and 4% to 6% for vitamin B12 levels. The
creatinine clearance was calculated using the equation of
Cockcroft and Gault [17].
Identification of the TCN2 776C>G polymorphism
was performed using an amplification refractory mu-
tation system [9]. Identification of the 677C>T transi-
tion in MTHFR was performed as previously described
[18, 19].
Statistical analyses
The SAS for Windows (release 8.2) statistical soft-
ware was used for all analyses (The SAS Institute Inc.,
Cary, NC, USA). We described important patient char-
acteristics using mean values and standard deviations, or
medians and the 25th/75th percentiles for continuous
variables, and percentages for categorical variables. As
the distributions of plasma vitamin B12, folate levels,
and total homocysteine were found to be skewed to the
right, and therefore nonnormally distributed, we used a
special case of general linear models for all advanced
analyses. The link function was chosen to be linear and
spread was determined to follow a gamma distribution
(in SAS, PROC GENMOD, LINK = IDENTITY, DIST
= GAMMA). Such an approach provides unbiased es-
timates of effect for positively skewed data without the
need to conduct data transformation(e.g., to a logarith-
mic scale [20, 21]). Like in previous work, we used such
models both for univariate and multivariate analyses [5,
7]. Three sets of analyses were conducted, the outcomes
being plasma levels of vitamin B12, folate, and total ho-
mocysteine concentration, respectively. Independent co-
variates included patient age (in decades), gender, time
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Table 2. Plasma vitamin B12, folate, and total homocysteine levels of
732 kidney graft recipients according to TCN2 genotypes
TCN2 776C>G genotype
CC CG GG
Number 204 383 145
Plasma vitamin B12 pmol/L 263 ± 197 253 ± 145 254 ± 116
Plasma folate nmol/L 15.2 ± 17.2 14.8 ± 11.5 14.5 ± 6.9
Plasma total homocysteine 16.8 ± 7.4 17.0 ± 9.8 17.8 ± 7.4
lmol/L
Mean ± SD.
since kidney transplantation (<2 vs. ≥2 months), and cat-
egories of underlying kidney disease (diabetic nephropa-
thy, glomerulonephritis, interstitial nephritis, polycystic
kidney disease, miscellaneous other defined, and kid-
ney disease not otherwise defined). We calculated each
patient’s body mass index (BMI), categorized in quin-
tiles, as the weight in kilograms divided by the squared
height in meters, and defined quintiles of the plasma lev-
els of folate and vitamin B12, respectively. For each pa-
tient, we estimated the creatinine clearance/glomerular
filtration rate (GFR) using the Cockcroft-Gault approx-
imation, [17] and then staged renal function in accor-
dance with Kidney/Dialysis Outcomes Quality Initiative
(K/DOQI) guidelines (>90, 60 to 90, 30 to 60, <30
mL/min/1.73 m2)[22]. We created dummy covariates for
the genotypes of MTHFR 677C>T as well as for het-
erozygosity and homozygosity of TCN2 776C>G. All
two-way interactions between these genetic variants
were also tested for significance. All multivariate mod-
els adjusted for age, gender, BMI, estimated GFR, time
since transplantation, underlying kidney disease, geno-
type MTHFR 677C>T, plasma levels of vitamin B12 (in
models of plasma folate and total homocysteine), and
plasma levels of folate (in models of plasma vitamin B12
and total homocysteine).
RESULTS
Patients, vitamin status, and genotypes
The characteristics of all study participants are indi-
cated in Table 1. The mean age in the cohort was 51.8
years, 60% were male, and more than half of the patients
were obese or overweight (i.e., BMI >25 kg/m2). Table 1
also depicts vitamin status and plasma total homocysteine
levels of all 732 kidney graft recipients. Exactly half of the
patients had elevated total homocysteine (>15 lmol/L),
only two patients (0.3%) were below reference for plasma
folate (<3.4 nmol/L), and 66 patients (9.0%) had vitamin
B12 levels below the reference threshold (<118 pmol/L).
The allele frequency of TCN2 776G was 0.46; 383 pa-
tients (study population prevalence 52.3%) were het-
erozygous and 145 patients (19.8%) were homozygous for
the mutation (Table 2). The allele frequency of MTHFR
677T was 0.32; 309 patients (study population prevalence
42.2%) were heterozygous and 79 patients (10.8%) were
homozygous for the mutation.
Effect of TCN2 genotypes on plasma vitamin B12
concentrations
Mean plasma levels of vitamin B12 stratified by TCN2
genotype are shown in Table 2. Univariate analyses
did not reveal any associations between TCN2 geno-
type and plasma vitamin B12. Similarly, after multivari-
ate adjustment for age, gender, BMI, estimated GFR,
time since transplantation, underlying kidney disease,
MTHFR 677C>T genotype, and plasma levels of folate,
we did not detect any differences in any of the three out-
comes variables by TCN2 genotype status (Table 3).
Effect of TCN2 genotypes on plasma folate
concentrations
Mean plasma levels of folate stratified by TCN2 geno-
types are shown in Table 2. We tested whether the allelic
variants of TCN2 were associated with folate plasma lev-
els using general linear models. Neither in univariate, nor
in multivariate analyses did we find any associations be-
tween the allelic variants of the TCN2 gene and plasma
folate levels (Table 3). Excluding vitamin B12 plasma level
from the multivariate regression analysis did not change
these results.
Effect of TCN2 genotypes on plasma total
homocysteine concentrations
Mean total homocysteine plasma levels according to
TCN2 genotypes are indicated in Table 2. When testing
whether TCN2 776C>G was associated with total ho-
mocysteine plasma levels in regression models, we did
not detect any significant associations between any of
the allelic variants and total homocysteine plasma lev-
els both in univariate, and in multivariate analyses (Table
3). These results did not change materially whether or not
we included vitamin B12 and/or folate in the multivariate
models.
DISCUSSION
In this study of 732 kidney transplant recipients, we an-
alyzed whether allelic variants of a recently discovered
polymorphism, TCN2 776C>G, were associated with
plasma levels of vitamin B12, folate, or total homocys-
teine. This population is the largest thus far to be studied
with regard to this specific research question and suffi-
ciently powered to detect even small effects if present. Us-
ing general linear models and accounting for the skewed
outcomes variables we did not find any associations be-
tween TCN2 genotype and plasma vitamin B12, folate,
or total homocysteine levels, respectively. These findings
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Table 3. Estimated univariate and multivariate linear associations between TCN2 genotypes and plasma vitamin B12, folate, and total
homocysteine (tHcy) levels
Univariate results Multivariate resultsa
Outcome modeled by
TCN2 genotype Estimate 95% CI P value Estimate 95% CI P value
Plasma vitamin B12 (vitamin B12 (vitamin B12
in pmol/L) in pmol/L)
776CC — (referent) — — (referent) —
776CG −10.3 (−32.3; 10.9) 0.361 −13.8 (−35.9; 8.23) 0.219
776GG −9.3 (−36.6; 18.1) 0.508 −2.0 (−29.3; 25.3) 0.886
Plasma folate (folate in nmol/L) (folate in nmol/L)
776CC — (referent) — — (referent) —
776CG −0.47 (−1.69; 0.74) 0.447 0.06 (−1.04; 1.17) 0.909
776GG −0.76 (−2.26; 0.73) 0.318 0.14 (−1.23; 1.51) 0.841
Plasma total homocysteine (total homocysteine (total homocysteine
in lmol/L) in lmol/L)
776CC — (referent) — — (referent) —
776CG 0.24 (−0.94; 1.42) 0.694 0.66 (−0.16; 1.48) 0.114
776GG 1.05 (−0.47; 2.57) 0.177 0.54 (−0.55; 1.64) 0.329
aAll multivariate models simultaneously accounted for age, gender, body mass index, estimated glomerular filtration rate, time since transplantation, underlying
kidney disease, and MTHFR 677C>T, and of TCN2 776C>G genotype. Plasma levels of vitamin B12 were additionally included in models of plasma folate and total
homocysteine. Plasma levels of folate were additionally included in models of plasma vitamin B12 and total homocysteine.
arose from multivariate models that accounted for im-
portant potential confounders.
Our findings indicating the lack of an association be-
tween TCN2 genotype and vitamin B12 plasma levels are
consistent with most of the previous reports from other
populations [8–13, 23, 24]. Only two studies have de-
scribed an association between TCN2 genotype and the
proportion of vitamin B12 bound to holo-TC II [11, 12].
Thus, the present study provides further evidence that the
single nucleotide polymorphism under study does not in-
fluence plasma levels of vitamin B12.
Similarly, our findings support the existing evidence on
no association between the allelic variants of TCN2 and
plasma folate levels. Several studies in healthy subjects
[9–11, 23] and in patients with dementia or vascular dis-
ease have failed to find such an association [10, 23, 24].
Our analyses suggesting the lack of an association be-
tween the allelic variants of the TCN2 776C>G genotype
and total homocysteine levels add to a body of conflicting
evidence. Several studies have found a positive associa-
tion of these allelic variants compared to the wild-type
in various populations: healthy individuals [9, 12, 13],
patients with vascular disease [13], and mothers of chil-
dren with neural tube defects [12]. Studies of healthy el-
derly individuals, of dementia patients, and patients with
thrombotic disease have failed to detect such an associa-
tion [10, 11, 23, 24]. Moreover, the present study of renal
transplant patients is in agreement with a previous study
of hemodialysis patients reporting no major influence of
TCN2 776C>G on total homocysteine levels. To explain
these discrepant study results, it has been suggested that
age might modify the effect of the TCN2 polymorphism
on total homocysteine plasma levels in that this effect
may be restricted to younger individuals [25]. However,
neither interaction terms of age and the TCN2 allelic vari-
ants, nor models stratified by age at midpoint supported
this notion and, thus, failed to show an effect. Some ex-
planations for the discrepancy between the null findings
of our and four previous studies [10, 11, 23, 24] versus
several other reports that indicated a positive but weak
association between the TCN2 polymorphism and total
homocysteine levels [8, 9, 12, 13] have been recently re-
ported. They include publication bias, failure to attribute
results to chance, and inadequate sample size [26, 27].
The present study shares its limitations with previous
studies using this sample of renal transplant recipients
[5, 7]. Findings from a population of renal transplant pa-
tients may not be representative of other populations.
The cross-sectional design makes it possible that time-
related biases are operational, most importantly survival
bias. Certain genotype combinations might affect eligi-
bility for transplantation or patient survival so that such
patients are less likely to be represented in the analysis. A
formal test of the hypothesis that the relative frequencies
of the three TCN2 allelic variants change with time since
transplantation remained non-significant, providing evi-
dence against presence of survival bias (data not shown).
In any case, such a bias would solely influence preva-
lence estimates of various genotypes, but not necessarily
associations between allelic variants and folate or total
homocysteine plasma levels. Other than in our previous
study of patients on hemodialysis, we did not have any
information on TC II levels [8]. We did not assess dietary
intake of folate or vitamin B12, which should not be an
issue, because none of the patients received folic acid or
multivitamin supplements and so dietary folate or vita-
min B12 intake can be assumed to be within a relatively
narrow range. Finally, we neither used a microbiologic
assay for estimation of folate supply, nor was red blood
cell folate measured. Trimethoprim use has been shown
to increase total homocysteine plasma levels [28], but was
not assessed in this study since it can be assumed to be
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independent of TCN2 genotype and, hence, cannot con-
found the associations of interest. Inclusion of informa-
tion on the specific immunosuppressive regimen at time
of blood sampling in the models did not change the re-
sults confirming earlier findings that immunosuppressive
drugs are not associated with the outcomes studied herein
(results not shown) [29, 30].
CONCLUSION
From a large population we provide compelling evi-
dence that the recently described TCN2 776C>G poly-
morphism is not a determinant of plasma vitamin B12,
folate, or total homocysteine levels in patients with a
functioning kidney graft. Further research in other pop-
ulations is necessary to ensure generalizability of these
findings and to elucidate the true relationship between
the TCN2 776C>G polymorphism and plasma total ho-
mocysteine levels.
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